隴神戎發(300534.SZ):公司目前沒有涉及合成生物領域
格隆匯5月9日丨隴神戎發(300534.SZ)在投資者互動平台表示,公司專注於中成藥在疾病治療和預防領域的研發、生產和銷售,現有元胡止痛滴丸、宣肺止嗽合劑、鞣酸小檗鹼膜、七味温陽膠囊和酸棗油仁滴丸5個獨家品種。子公司普安製藥主打產品宣肺止嗽合劑採用“水提醇沉”的生產工藝,該工藝成熟穩定,有效成分的提取率高,產品療效更加顯著,並已申請獲得相關技術專利;其子公司普迪安製藥致力於研究口溶膜系列產品,其新研發產品 PDA 口溶膜已上報國家藥監局並取得受理通知書,食用薄荷膜(薄荷爽口片)已取得食品生產許可證。公司目前沒有涉及合成生物領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.